Behavioral Health Program for Short-Stay Nursing Facility Residents & Care Partners (BRISK)
Building Resilience in Skilled Nursing Care: A Behavioral Health Intervention for Residents & Care Partners
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Makenna E Law, BS
- Phone Number: 617-643-9406
- Email: brisk@mgb.org
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Recruiting
- Massachusetts General Hospital
-
Contact:
- BRISK Study Team
- Phone Number: 617-643-9406
- Email: brisk@mgb.org
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patient and care partner both aged ≥ 18 years
- Patient with care partner (known person providing regular health-related, socioemotional, or practical support) willing to participate
- Patient reporting depression symptoms on a screening tool (Patient Health Questionnaire)
Exclusion Criteria:
- Patient intended length of nursing facility stay < 7 days
- Patient evidencing more than mild impairment on a cognitive screen (Brief Interview for Mental Status)
- Patient's roommate in skilled nursing facility already enrolled in study/intervention
- Either patient or care partner reporting high risk of suicidality, based on a standardized safety assessment tool
- Either patient or care partner participating in newly initiated psychotherapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: InSTILL
Participants in this arm will participate in the Interventions for Stressful Transitions in Later Life (InSTILL), a behavioral health intervention tailored to the needs of short stay nursing facility residents and their primary care partner.
InSTILL includes 8 sessions (2x per week for about 4 weeks) delivered in person or remotely.
Both participants (e.g., resident and care partner) attend all sessions together, facilitated by a trained clinician.
|
The Interventions for Stressful Transitions in Later Life (InSTILL) intervention is for skilled nursing facility residents and their care partners experiencing elevated levels of psychological distress.
The intervention is designed to improve life management skills, emotion regulation skills, and dyadic coping skills with the goal of reducing depression symptoms among both dyad members (i.e., resident and care partner).
|
|
No Intervention: Minimally Enhanced Usual Care
Participants in this group will receive a psychoeducational pamphlet with enhanced referrals for community support resources.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Treatment Credibility
Time Frame: peri-intervention
|
3-item self-report measure of participant's belief regarding how helpful the intervention will be for them.
Higher scores (min = 0, max = 30) scores indicate greater credibility.
|
peri-intervention
|
|
Client Satisfaction Questionnaire
Time Frame: immediately after the intervention
|
3-item self-report measure assessing patient satisfaction with the program.
Higher total scores (min = 3, max = 12) indicate greater satisfaction.
|
immediately after the intervention
|
|
Feasibility of Recruitment
Time Frame: baseline, pre-intervention
|
Percentage of eligible approached dyads that are enrolled into the study.
|
baseline, pre-intervention
|
|
Feasibility of Data Collection
Time Frame: 1 month follow-up
|
Percentage of all participants with no measure fully missing at follow-up.
|
1 month follow-up
|
|
Treatment Adherence
Time Frame: immediately after the intervention
|
Percentage of InSTILL participants completing 5/8 sessions
|
immediately after the intervention
|
|
Clinician Fidelity
Time Frame: immediately after the intervention
|
Percentage of InSTILL sessions delivered with 100% adherence on a study-specific Fidelity Checklist.
|
immediately after the intervention
|
|
Adverse Events
Time Frame: 1 month follow-up
|
Any adverse events related to participation in the study.
|
1 month follow-up
|
|
Treatment Acceptability Survey
Time Frame: immediately after the intervention
|
Percentage of InSTILL participants scoring above the scale midpoint on all 9 Treatment Acceptability Survey items (developed for the current study).
|
immediately after the intervention
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
PHQ-9
Time Frame: baseline, pre-intervention; immediately after the intervention; 1 month follow-up
|
9-item self-report measure of depression symptoms.
Higher scores (min=0, max=27) indicate greater depressive symptoms.
|
baseline, pre-intervention; immediately after the intervention; 1 month follow-up
|
|
Selection, Optimization, and Compensation in Everyday Use
Time Frame: baseline, pre-intervention; immediately after the intervention; 1 month follow-up
|
4-item self-report measure of the application of selection, optimization, and compensation strategies in daily life.
|
baseline, pre-intervention; immediately after the intervention; 1 month follow-up
|
|
Committed Action Questionnaire
Time Frame: baseline, pre-intervention; immediately after the intervention; 1 month follow-up
|
8-item self-report measure of pursuit of valued goals despite challenges and difficulties
|
baseline, pre-intervention; immediately after the intervention; 1 month follow-up
|
|
Perceptions of Collaboration Questionnaire
Time Frame: baseline, pre-intervention; immediately after the intervention; 1 month follow-up
|
12-item self-report measure of dyadic coping, including collaboration and interpersonal enjoyment.
|
baseline, pre-intervention; immediately after the intervention; 1 month follow-up
|
|
General Anxiety Disorder-7
Time Frame: baseline, pre-intervention; immediately after the intervention; 1 month follow-up
|
7-item self-report measure of anxiety symptoms.
|
baseline, pre-intervention; immediately after the intervention; 1 month follow-up
|
|
Euro QoL-5D 5L
Time Frame: baseline, pre-intervention; immediately after the intervention; 1 month follow-up
|
6-item self-report measure of subjective health-related quality of life.
|
baseline, pre-intervention; immediately after the intervention; 1 month follow-up
|
|
Relationship Assessment Scale
Time Frame: baseline, pre-intervention; immediately after the intervention; 1 month follow-up
|
Single-item self-report measure of relationship satisfaction with study partner.
|
baseline, pre-intervention; immediately after the intervention; 1 month follow-up
|
|
Preparedness for Future Care
Time Frame: baseline, pre-intervention; immediately after the intervention; 1 month follow-up
|
5-item self-report measure of active preparation for future health care needs.
|
baseline, pre-intervention; immediately after the intervention; 1 month follow-up
|
|
COREQ
Time Frame: immediately after the intervention
|
4-item self-report of nursing facility satisfaction.
|
immediately after the intervention
|
|
University of Washington Resilience Scale Short Form
Time Frame: baseline, pre-intervention; immediately after the intervention; 1 month follow-up
|
4-item self-report of an individual's perceived resilience.
|
baseline, pre-intervention; immediately after the intervention; 1 month follow-up
|
|
Zarit Burden Interview
Time Frame: baseline, pre-intervention; immediately after the intervention; 1 month follow-up
|
4-item self-report screener of caregiver burden.
Administered to care partners only.
|
baseline, pre-intervention; immediately after the intervention; 1 month follow-up
|
|
Psychotropic medication use
Time Frame: baseline, pre-intervention; immediately after the intervention; 1 month follow-up
|
Chart or self reported psychotropic medication use
|
baseline, pre-intervention; immediately after the intervention; 1 month follow-up
|
|
Re-hospitalization
Time Frame: immediately after the intervention; 1 month follow-up
|
Resident re-hospitalization during the study period
|
immediately after the intervention; 1 month follow-up
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Evan Plys, PhD, Massachusetts General Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2025P0001624
- K23AG078410 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.